Send to

Choose Destination
Cancer Lett. 2008 Nov 8;270(2):328-36. doi: 10.1016/j.canlet.2008.05.024. Epub 2008 Jul 16.

PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.

Author information

Departamento de Biología Molecular and Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC-IDICAN, Facultad de Medicina, 39011 Santander, Spain.


The PU.1 transcription factor is a crucial regulator of hematopoiesis which expression is altered in various leukemic processes. Our previous work in chronic myeloid leukemia (CML) cells demonstrated that interferon-alpha upregulated PU.1 expression. Here we show that expression of PU.1 is severely impaired in patients with CML at diagnosis. However, the PU.1 suppression is abrogated in patients in remission, after interferon-alpha or imatinib treatment. These effects are not found in patients with other myeloproliferative diseases such as polycythemia vera or essential thrombocythemia. PU.1 could, therefore, be used as an additional marker of the response to the treatment of the CML.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Digital CSIC Spanish National Research Council
Loading ...
Support Center